Sökning: L773:1879 0852 >
Frondoside A enhanc...
-
Al Shemaili, JasemUppsala universitet,Institutionen för farmaceutisk biovetenskap
(författare)
Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2014
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-224321
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-224321URI
-
https://doi.org/10.1016/j.ejca.2014.01.002DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Pancreatic cancer has a very poor prognosis. While gemcitabine is the mainstay of therapy and improves quality of life, it has little impact on survival. More effective treatments are desperately needed for this disease. Frondoside A is a triterpenoid glycoside isolated from the Atlantic sea cucumber, Cucumaria frondosa. Frondoside A potently inhibits pancreatic cancer cell growth and induces apoptosis in vitro and in vivo. The aim of the present study was to investigate whether frondoside A could enhance the anti-cancer effects of gemcitabine. Effects of frondoside A and gemcitabine alone and in combination on proliferation were investigated in two human pancreatic cancer cell lines, AsPC-1 and S2013. To investigate possible synergistic effects, combinations of low concentrations of the two drugs were used for a 72 h treatment period in vitro. Growth inhibition was significantly greater with the drug combinations than their additive effects. Combinations of frondoside A and gemcitabine were tested in vivo using the athymic mouse model. Xenografts of AsPC-1 and S2013 cells were allowed to form tumours prior to treatment with the drugs alone or in combination for 30 days. Tumours grew rapidly in placebo-treated animals. Tumour growth was significantly reduced in all treatment groups. At the lowest dose tested, gemcitabine (4 mg/kg/dose), combined with frondoside A (100 mu g/kg/day) was significantly more effective than with either drug alone. To conclude: The present data suggest that combinations of frondoside A and gemcitabine may provide clinical benefit for patients with pancreatic cancer.
Ämnesord och genrebeteckningar
-
Pancreatic cancer
-
Frondoside A
-
Gemcitabine
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Mensah-Brown, E.
(författare)
-
Parekh, K.
(författare)
-
Thomas, S. A.
(författare)
-
Attoub, S.
(författare)
-
Hellman, BjörnUppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)bjornhel
(författare)
-
Nyberg, FredUppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)frednybe
(författare)
-
Adem, A.
(författare)
-
Collin, P.
(författare)
-
Adrian, T. E.
(författare)
-
Uppsala universitetInstitutionen för farmaceutisk biovetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Journal of Cancer: Elsevier BV50:7, s. 1391-13980959-80491879-0852
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Al Shemaili, Jas ...
-
Mensah-Brown, E.
-
Parekh, K.
-
Thomas, S. A.
-
Attoub, S.
-
Hellman, Björn
-
visa fler...
-
Nyberg, Fred
-
Adem, A.
-
Collin, P.
-
Adrian, T. E.
-
visa färre...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet